| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/07/2013 | CA2843782A1 Anti-inflammatory steroids condensed in position 16,17 with pyrrolidine ring |
| 02/07/2013 | CA2843643A1 Compositions and methods for the treatment of hiv |
| 02/07/2013 | CA2843636A1 Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
| 02/07/2013 | CA2843599A1 Subcutaneous needle assisted jet injection administration of methotrexate |
| 02/07/2013 | CA2843595A1 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| 02/07/2013 | CA2843552A1 Protein having activity to promote fatty acid chain elongation, gene encoding the same and use thereof |
| 02/07/2013 | CA2843535A1 Treatment of heart failure and related conditions |
| 02/07/2013 | CA2843436A1 Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| 02/07/2013 | CA2843401A1 3-hydroxyanthranilic acid (3-haa) therapy for prevention and treatment of hyperlipidemia and its cardiovascular complications |
| 02/07/2013 | CA2843383A1 Amidine compound or salt thereof |
| 02/07/2013 | CA2843338A1 Selective inhibition of malt1 protease by phenothiazine derivatives |
| 02/07/2013 | CA2843330A1 Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| 02/07/2013 | CA2843240A1 Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof |
| 02/07/2013 | CA2843238A1 N-hetero-ring-substituted amide derivative |
| 02/07/2013 | CA2843224A1 Treatment of type 2 diabetes with fty720 |
| 02/07/2013 | CA2843139A1 Corticosteroids for the treatment of joint pain |
| 02/07/2013 | CA2842954A1 Double-stranded oligonucleotide compounds for treating hearing and balance disorders |
| 02/07/2013 | CA2842906A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | CA2842802A1 Non-digestible capsules for the delivery of fluid absorbing materials |
| 02/07/2013 | CA2842707A1 Bile acid recycling inhibitors for treatment of pancreatitis |
| 02/07/2013 | CA2842577A1 Antiseptic composition |
| 02/07/2013 | CA2842493A1 Crizotinib for use in the treatment of cancer |
| 02/07/2013 | CA2842450A1 Insulin secretion promoting agents |
| 02/07/2013 | CA2842394A1 Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta |
| 02/07/2013 | CA2842364A1 Nuclear transport modulators and uses thereof |
| 02/07/2013 | CA2842362A1 Hydrazide containing nuclear transport modulators and uses thereof |
| 02/07/2013 | CA2841644A1 Pharmaceutical composition comprising ebastine and fluticasone |
| 02/07/2013 | CA2841572A1 Trans-clomiphene metabolites and uses thereof |
| 02/07/2013 | CA2839805A1 Pyridin-2(1h)-one derivatives as jak inhibitors |
| 02/07/2013 | CA2839126A1 Tamper-resistant tablet providing immediate drug release |
| 02/07/2013 | CA2839123A1 Tamper-resistant tablet providing immediate drug release |
| 02/07/2013 | CA2839122A1 Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| 02/06/2013 | EP2554550A1 Method for inhibiting hiv replication in mammal and human cells |
| 02/06/2013 | EP2554549A1 Oligosaccharides and oligosaccharides-protein conjugates derived from clostridium difficile polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools |
| 02/06/2013 | EP2554546A1 Pyripyropene derivative having acat2 inhibiting activity and stable to metabolizing enzymes |
| 02/06/2013 | EP2554544A1 Pyridin-2(1h)-one derivatives as jak inhibitors |
| 02/06/2013 | EP2554542A1 Phenylalanine derivative salt crystal |
| 02/06/2013 | EP2554541A1 Therapeutic agent or prophylactic agent for fibromyalgia |
| 02/06/2013 | EP2554532A1 Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta |
| 02/06/2013 | EP2554184A1 Preventive and/or remedy for hand and foot syndrome |
| 02/06/2013 | EP2554178A1 Expression modulator for clock gene period |
| 02/06/2013 | EP2554177A1 Expression modulator for clock gene bmal |
| 02/06/2013 | EP2554174A1 Method for treatment of diseases |
| 02/06/2013 | EP2554173A1 Method for treatment of diseases |
| 02/06/2013 | EP2554172A1 Method for treatment of diseases |
| 02/06/2013 | EP2554171A1 Method for treatment of diseases |
| 02/06/2013 | EP2554170A1 Method for treatment of diseases |
| 02/06/2013 | EP2554169A1 Pharmaceutical preparation comprising phenylalanine derivative |
| 02/06/2013 | EP2554168A1 Controlled release pharmaceutical composition |
| 02/06/2013 | EP2554167A1 New use of l-histidine and derivatives thereof |
| 02/06/2013 | EP2554166A1 Oil and fat composition for prevention or treatment of diabetes |
| 02/06/2013 | EP2554165A1 Prophylactic agent or therapeutic agent for diabetes or obesity |
| 02/06/2013 | EP2554164A1 Pharmaceutical formulation based on ibuprofen and codeine having having improved stability |
| 02/06/2013 | EP2554163A1 Neurodegenerative disease therapeutic agent |
| 02/06/2013 | EP2554162A1 Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia |
| 02/06/2013 | EP2554058A1 Functional food supplement intended, in particular, for nutrition and for prevention and improvement in cases of neurological alterations, neurodegenerative alterations or cognitive disorders |
| 02/06/2013 | EP2554057A1 Enteral or oral food product intended, in particular, for nutrition and for the prevention and improvement of neurological alterations, neurodegenerative alterations or cognitive disorders |
| 02/06/2013 | EP2554056A1 Nutritional compositions with coated lipid globules |
| 02/06/2013 | EP2553123A1 Methods for enhancing nucleic acid hybridization |
| 02/06/2013 | EP2553098A2 Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
| 02/06/2013 | EP2553019A1 Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| 02/06/2013 | EP2552933A1 Purine nucleoside phosphoramidate |
| 02/06/2013 | EP2552932A1 Adenosine compounds and their use thereof |
| 02/06/2013 | EP2552931A2 Stereoselective synthesis of phosphorus containing actives |
| 02/06/2013 | EP2552930A2 Nucleoside phosphoramidates |
| 02/06/2013 | EP2552924A1 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs |
| 02/06/2013 | EP2552923A1 Macrocyclic integrase inhibitors |
| 02/06/2013 | EP2552922A1 Substituted pyrrolotriazines as protein kinase inhibitors |
| 02/06/2013 | EP2552921A1 Purine compounds |
| 02/06/2013 | EP2552920A1 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| 02/06/2013 | EP2552919A1 Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| 02/06/2013 | EP2552918A1 N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors |
| 02/06/2013 | EP2552916A1 Purine compounds used as cb2 agonists |
| 02/06/2013 | EP2552915A1 Compounds and method for treatment of hiv |
| 02/06/2013 | EP2552914A1 Benzonaphthyridinamines as autotaxin inhibitors |
| 02/06/2013 | EP2552910A1 New polymorph |
| 02/06/2013 | EP2552909A1 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists |
| 02/06/2013 | EP2552908A2 Heterocyclic compounds and their uses |
| 02/06/2013 | EP2552907A1 Pyridyltriazoles |
| 02/06/2013 | EP2552906A1 Cgrp receptor antagonist |
| 02/06/2013 | EP2552905A1 B-raf kinase inhibitors |
| 02/06/2013 | EP2552902A1 Non-nucleoside reverse transcriptase inhibitors |
| 02/06/2013 | EP2552893A1 Antibacterial isoquinolin-3-ylurea derivatives |
| 02/06/2013 | EP2552890A1 Polycyclic tetracycline compounds |
| 02/06/2013 | EP2552888A1 "trpv1 vanilloid receptor antagonists with a bicyclic portion" |
| 02/06/2013 | EP2552887A2 Indolyl or indolinyl hydroxamate compounds |
| 02/06/2013 | EP2552886A1 Cytokine inhibitors |
| 02/06/2013 | EP2552885A1 Neuraminidase inhibitors |
| 02/06/2013 | EP2552486A1 Transdermal delivery patch |
| 02/06/2013 | EP2552484A1 Methods and compositions for reducing parathyroid levels |
| 02/06/2013 | EP2552460A1 Polymers for delivering molecules of interest |
| 02/06/2013 | EP2552459A1 Method of treating inflammation |
| 02/06/2013 | EP2552457A1 New biomaterial from wharton's jelly umbilical cord |
| 02/06/2013 | EP2552456A1 Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
| 02/06/2013 | EP2552455A2 Transcription factor decoys |
| 02/06/2013 | EP2552454A1 ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS |
| 02/06/2013 | EP2552453A2 Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| 02/06/2013 | EP2552452A1 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 02/06/2013 | EP2552451A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 02/06/2013 | EP2552450A1 Use of novel pan-cdk inhibitors for treating tumors |